TW202222343A - 治療ox40相關疾病之方法 - Google Patents

治療ox40相關疾病之方法 Download PDF

Info

Publication number
TW202222343A
TW202222343A TW110137584A TW110137584A TW202222343A TW 202222343 A TW202222343 A TW 202222343A TW 110137584 A TW110137584 A TW 110137584A TW 110137584 A TW110137584 A TW 110137584A TW 202222343 A TW202222343 A TW 202222343A
Authority
TW
Taiwan
Prior art keywords
weeks
antibody
treatment
administration
ser
Prior art date
Application number
TW110137584A
Other languages
English (en)
Chinese (zh)
Inventor
佐藤光男
永田吉範
大瀧顕司
今井信行
島辺宗健
Original Assignee
日商協和麒麟股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商協和麒麟股份有限公司 filed Critical 日商協和麒麟股份有限公司
Publication of TW202222343A publication Critical patent/TW202222343A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW110137584A 2020-10-09 2021-10-08 治療ox40相關疾病之方法 TW202222343A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063089809P 2020-10-09 2020-10-09
US63/089,809 2020-10-09
US202063116365P 2020-11-20 2020-11-20
US63/116,365 2020-11-20
US202163233592P 2021-08-16 2021-08-16
US63/233,592 2021-08-16

Publications (1)

Publication Number Publication Date
TW202222343A true TW202222343A (zh) 2022-06-16

Family

ID=81126528

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110137584A TW202222343A (zh) 2020-10-09 2021-10-08 治療ox40相關疾病之方法

Country Status (11)

Country Link
US (1) US20230383001A1 (cg-RX-API-DMAC7.html)
EP (1) EP4225371A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023545084A (cg-RX-API-DMAC7.html)
KR (1) KR20230084166A (cg-RX-API-DMAC7.html)
CN (1) CN116437955A (cg-RX-API-DMAC7.html)
AU (1) AU2021358274A1 (cg-RX-API-DMAC7.html)
CA (1) CA3198414A1 (cg-RX-API-DMAC7.html)
IL (1) IL301935A (cg-RX-API-DMAC7.html)
MX (1) MX2023004113A (cg-RX-API-DMAC7.html)
TW (1) TW202222343A (cg-RX-API-DMAC7.html)
WO (1) WO2022075476A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.
IL326123A (en) * 2023-07-25 2026-03-01 Inmagene Pte Ltd Methods of treating alopecia areata and atopic dermatitis
WO2025244002A1 (ja) * 2024-05-21 2025-11-27 国立大学法人京都大学 ベンダムスチンによるt細胞の減少を抑制するために使用されるt細胞減少抑制剤
WO2025259719A1 (en) * 2024-06-10 2025-12-18 Walden Biosciences, Inc. Method of administering an anti-soluble urokinase plasominogen activator receptor antibody for the treatment of kidney disease
WO2026145427A1 (en) * 2024-12-30 2026-07-09 Hanx Biopharmaceuticals (Wuhan) Co., Ltd. Bispecific antibodies targeting ox40 and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類cd134(ox40)之人類單株抗體及其製造及使用方法
WO2017134292A1 (en) * 2016-02-04 2017-08-10 Glenmark Pharmaceuticals S.A. Anti-ox40 antagonistic antibodies for the treatment of atopic dermatitis
US11596699B2 (en) * 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
RU2759630C2 (ru) * 2016-09-22 2021-11-16 Ридженерон Фармасьютикалз, Инк. Способы лечения тяжелого атопического дерматита путем введения ингибитора il-4r
TWI787203B (zh) * 2016-09-23 2022-12-21 美商建南德克公司 Il-13拮抗劑用於治療異位性皮炎之用途
WO2019229155A1 (en) * 2018-05-31 2019-12-05 Glenmark Pharmceuticals S.A. Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders

Also Published As

Publication number Publication date
US20230383001A1 (en) 2023-11-30
CA3198414A1 (en) 2022-04-14
JP2023545084A (ja) 2023-10-26
KR20230084166A (ko) 2023-06-12
AU2021358274A1 (en) 2023-05-25
WO2022075476A1 (en) 2022-04-14
EP4225371A4 (en) 2024-11-20
MX2023004113A (es) 2023-06-29
IL301935A (en) 2023-06-01
AU2021358274A9 (en) 2024-05-30
EP4225371A1 (en) 2023-08-16
CN116437955A (zh) 2023-07-14

Similar Documents

Publication Publication Date Title
JP6353838B2 (ja) Il−4rアンタゴニストを投与することによるアトピー性皮膚炎を処置するための方法
WO2022075476A1 (en) Method for treating ox40 related disease
JP2022023051A (ja) 瘻孔を伴うクローン病の治療用ベドリズマブ
CN112153982A (zh) 用于通过施用il-4r抑制剂治疗特应性皮炎的方法
US20240059783A1 (en) Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders
CN109963577A (zh) 用于通过施用il-4r抑制剂治疗严重特应性皮炎的方法
US20230131598A1 (en) Combination treatment for cancer
TW202434633A (zh) 治療甲狀腺眼疾之方法
US20230140694A1 (en) Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies
TWI870471B (zh) 全身性硬化症治療用醫藥組合物
US20230149543A1 (en) Combination treatment for cancer based upon an icos antbody and a pd-l1 antibody tgf-bets-receptor fusion protein
JP2023506779A (ja) 慢性移植片対宿主病の処置用抗体
JP2024517796A (ja) 抗baffr抗体を使用するループス腎炎の治療
EP4337692A2 (en) Methods of treating dermatomyositis
JP2023504679A (ja) インターロイキン-17(il-17)アンタゴニストを使用して扁平苔癬を治療する方法
KR102284244B1 (ko) Il-4r 길항제 투여로 아토피성 피부염을 치료하는 방법
WO2025214333A1 (zh) 抗tslp抗体治疗与tslp相关的炎症疾病的方法
JP2024516019A (ja) 抗baffr抗体を使用する全身性エリテマトーデスのための治療
CN121889429A (zh) 用于治疗嗜酸性肉芽肿性多血管炎的IL-5R-α抗体
TW202535463A (zh) Anca相關血管炎之治療
CN108473576A (zh) 用于治疗复发形式的多发性硬化的方法